The HCMV-NEW-ABSTRATEGY project aims to develop innovative treatments for Human Cytomegalovirus (HCMV), a complex pathogen that poses risks to immunocompromised individuals and unborn children. The team will study multiple surface proteins to understand and effectively combat HCMV. Using this knowledge and advanced equipment, they plan to isolate clinically protective antibodies from individuals with strong immune responses against HCMV. They will refine these antibodies and explore their various effector functions to maximize their therapeutic potential. The scientists are committed to translating their research into clinical applications, improving the health of at-risk groups such as immunocompromised and unborn children.

Here you can find further information.